English | Español
Patient Daily | Feb 8, 2026

AstraZeneca acquires full rights to AbelZeta’s cancer therapy for $630 million
Patient Daily | Feb 8, 2026

GSK acquires RAPT Therapeutics for $2.2B under new CEO Luke Miels
Patient Daily | Feb 8, 2026

Biohaven outlines new strategy after setbacks and prepares muscle-sparing drug study
Patient Daily | Feb 8, 2026

CDMOs look to FDA's PreCheck program for support at new US production sites
Patient Daily | Feb 8, 2026

Penn Medicine earns national recognition for top clinical research achievements
Patient Daily | Feb 8, 2026

ACAAI offers guidance for an allergy-safe Valentine’s Day
Patient Daily | Feb 8, 2026

HonorHealth Research Institute administers new investigational stroke drug as part of national trial
Patient Daily | Feb 8, 2026

Study links long-term air pollution exposure with higher ALS risk

Trending
+ Pharmaceuticals
Patient Daily | Feb 3, 2026

Drug Channels President on 340B: 'no one knows where the 340B profits go, or which patients benefit'
+ Pharmaceuticals
Patient Daily | Feb 2, 2026

Clinical trial landscape shifts globally as China increases role in innovation
+ Pharmaceuticals
Patient Daily | Feb 5, 2026

FDA lifts hold on Intellia's phase III ATTR gene editing trial
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Summit Therapeutics’ ivonescimab faces key FDA decision as potential Keytruda competitor